VanEck Vectors Morningstar Durable Dividend ETF DURA 深 滬
等待開盤 10-08 09:30:00 美东时间
37.95
-0.129
-0.34%
華盛通- 最 高38.01
- 今 開38.01
- 成交量 1233股
- 最 低 37.95
- 昨 收 38.0792
- 總市值 3700.13万
- 52周最高 40.0927
- 市盈率 靜 --
- 換手率 0.13%
- 52周最低 30.1053
- 委 比 85.71%
- 總股本 97.50万
- 歷史最高 40.0927
- 量 比 0.86
- 振 幅 0.16%
- 歷史最低 12.7881
- 每 手 1
- 風險率 2.42%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多VanEck Vectors Morningstar Durable Dividend ETF declares quarterly distribution of $0.2609
VanEck Vectors Morningstar Durable Dividend ETF (DURA) - $0.2609. Payable Oct 06; for shareholders of record Oct 01; ex-div Oct 01. More on VanEck ETF Trust - VanEck Morningstar Durable Dividend ETF S...
10-02 04:19
A股盘前市场要闻速递（2026-08-19）
小程序：A股盘前市场要闻速递 重要新闻 1. 重大突破，我国首次实现火箭陆地回收 今天（8月19日），朱雀三号遥二运载火箭在东风商业航天创新试验区发射升空，火箭...
08-19 09:02
EyePoint rebounds after selloff despite multiple downgrades
After losing more than 65% in the previous session following a late-stage trial setback for its lead asset, Duravyu, EyePoint added 7% in morning trading despite facing multiple downgrades on Wall Str...
08-18 22:17
跨界牛股13天12板后提示风险：可能申请停牌核查 | 盘后公告精选
13天12板妖股再发异动公告，3000亿存储芯片龙头上半年净利大爆发，这一CPO概念股拿下8.68亿元算力采购合同......
08-18 21:11
EyePoint rises after enrollment update on Duravyu late-stage trials
Shares of EyePoint (EYPT) gained on Thursday after the company said that two late-stage trials for its lead asset, Duravyu, completed enrollments ahead of schedule, validating its confidence in the pr...
07-31 01:52
EyePoint completes Phase 3 DURAVYU enrollment for DME
EyePoint Pharmaceuticals ( ($EYPT) ) has provided an announcement. On July 30, ...
07-30 19:29
EyePoint to pay $4.6M to settle with DoJ over kickback claims
The U.S. Department of Justice announced on Friday that EyePoint Pharmaceuticals (EYPT) agreed to pay $4.6M to resolve allegations that the company paid kickbacks to certain healthcare providers to bo...
07-17 23:13
BrainStorm Cell Therapeutics Appoints Former FDA Associate Commissioner Peter J. Pitts As Board Director
BrainStorm Cell Therapeutics Inc. (OTCQB:BCLI), a leading developer of autologous stem cell therapies for neurodegenerative diseases, today announced that Peter J. Pitts has been appointed to the Company's Board of
05-28 19:49
